Choose your preferred way to stay informed of new case launches and settlement deadlines
The filed complaint alleges that Alector, Inc. made materially false and/or misleading statements and/or failed to disclose that: On October 22, 2025, Alector announced results from its Phase 2 INFRONT-3 clinical trial evaluating latozinemab (AL001) in patients with frontotemporal dementia due to a progranulin gene mutation (FTD-GRN). The company reported that “latozinemab did not demonstrate a clinical benefit” for slowing FTD-GRN progression in its 96-week double-blind trial. Following this news, ALEC’s stock price fell over 52% to open at $1.54 per share.
In order to be eligible to join the ALEC class action lawsuit, you must have incurred a loss on shares of Alector, Inc. purchased during the class period listed above.
TOP
